Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteospreypharma.com
CategoryBioTech
Emailinfo@ospreypharma...
Employees
Founded1998
DescriptionInflammatory/immune disease medications

Offices

People

CEO
Board of Directors

Funding

TOTAL $11.8M
FUNDING TOTAL $11.8M
Venture Round, 1/2007
Cascadia Partners
Desjardins Venture Capital
GeneChem
Ventures West
BDC Venture Capital
$5.92M
Series A, 5/2009
Partial Close, 5/2009
$5.89M

Tags

Osprey Pharmaceuticals USA

Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.

The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.

The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.

Recent Milestones

Videos

Screenshots

Osprey Pharmaceuticals USA screenshot
Above: Osprey Pharmaceuticals USA Screenshot -- #1
Uploaded: 6/19/09

Sources

  1. EDGAR [edit]
  2. Osprey picks up $3.8M more for immune disease treatments (venturebeat.com) [edit]
  3. SEC (sec.gov) [edit]
Edit This Page
Last Edited 2/4/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy